Physician profile
Darrell Lee Murray
NPI 1447250170
$12,278.65
in general payments reported to CMS, 2019-2025
45 companies · $1,986 in 2025
The $1,986 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,998 · 2020: $827 · 2021: $3,301 · 2022: $2,023 · 2023: $1,054 · 2024: $1,089 · 2025: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950 · Travel and Lodging: $1,102 · Education: $63.17 · Entertainment: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,949.88 |
| Travel and Lodging | $1,102.29 |
| Education | $63.17 |
| Entertainment | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,933.24 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,875.13 | 2021-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $1,433.46 | 2025 | |
| Abbvie INC. | $1,067.35 | 2020-2025 | |
| Amgen INC. | $654.53 | 2020-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $619.56 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Alkermes, INC. | $565.31 | 2019-2023 | Vivitrol |
| Biohaven Pharmaceuticals, INC. | $485.62 | 2021 | |
| Horizon Therapeutics Plc | $370.64 | 2019 | |
| Lilly USA, LLC | $321.15 | 2020-2024 | Mounjaro, Zepbound, Trulicity |
| Gilead Sciences, INC. | $309.03 | 2019-2021 | |
| Allergan, INC. | $287.82 | 2019-2020 | |
| Indivior INC. | $286.97 | 2020-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $257.10 | 2020-2024 | Rexulti, Abilify Maintena |
| Eisai INC. | $249.30 | 2021 |
Show all 43 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrell Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.